Sargent Bickham Lagudis LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.

Quarter-by-quarter ownership
Sargent Bickham Lagudis LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$8,000
-38.5%
1650.0%0.00%0.0%
Q2 2021$13,000
+44.4%
1650.0%0.00%0.0%
Q1 2021$9,000
-60.9%
165
-50.0%
0.00%0.0%
Q4 2020$23,000
+283.3%
330
+100.0%
0.00%0.0%
Q3 2020$6,000
+20.0%
165
-11.8%
0.00%0.0%
Q2 2020$5,0001870.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Crestline Management, LP 5,960,732$122,969,90114.32%
ARCH Venture Management, LLC 693,749$14,312,0429.30%
Flagship Pioneering Inc. 2,619,968$54,049,9403.92%
Casdin Capital, LLC 1,300,000$26,819,0002.97%
Yiheng Capital Management, L.P. 1,150,684$23,738,6111.21%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 154,000$3,172,4001.07%
SECTORAL ASSET MANAGEMENT INC 254,941$5,259,4331.02%
Temasek Holdings (Private) Ltd 6,895,992$142,264,3150.85%
Clarius Group, LLC 378,262$7,803,5450.74%
Artal Group S.A. 802,899$16,5640.71%
View complete list of DENALI THERAPEUTICS INC shareholders